Skip to content

Investigation of the Performance of Ostomy Base Plate

A Randomised Controlled Cross-over Study Investigating the Performance and Safety of the Ostomy Base Plate SSH

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01103466
Enrollment
41
Registered
2010-04-14
Start date
2010-04-30
Completion date
2010-12-31
Last updated
2013-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ileostomy - Stoma

Keywords

Ileostomy base plate

Brief summary

The purpose of this study is to evaluate the performance of Atlas (new base plate) on the degree of leakage under the base plate compared to SenSura and Conform 2. Our hypothesis is that Atlas will do better than the two comparator products.

Detailed description

Peristomal skin problems are reported to have a negative impact on the quality of life of people with a stoma and cause one third of all visits to a stoma care nurse. Stoma effluent in contact with the peristomal skin (leakage) appears to predispose patients to peristomal skin problems. To protect the skin against effluent, the appliance used for collection of stoma effluent should completely cover the peristomal skin close to the stoma. Coloplast has developed a new base plate (SSH) to improve security and increase comfort by minimizing leakage (seeping under the base plate) risk and thereby also the leakage related peristomal skin problems. The purpose with this clinical study is to evaluate the effect of the new base plate on the degree of leakage under the base plate compared to two existing base plates on the market. The study is a randomised controlled cross-over intervention study, where all study participants will test all three test products (SSH, Conform 2 and Sensura). Each test period will last 14 days. If 4 changes of base plates is not obtained during the 14 days, the test period will be prolonged until 4 base plate changes is obtained. However, the max test period of one type of product is 21 days. The participants will visit the study investigator at study start and at every shift to a new type of test product. At these visits they will answer questions about the tested product, have a peristomal skin examination and be instructed in how to use the next test products for the next treatment period. Evaluation of leakage and handling will occur via questionnaires the participants take home. 80 healthy participants with an ileostomy will be included in the study.

Interventions

DEVICEAtlas

Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.

DEVICESenSura

SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.

DEVICEConform 2

Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.

Sponsors

Coloplast A/S
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Have given written Informed Consent 2. Are at least 18 years old 3. Had their ileostomy for minimum 3 months with a size between 20-40 mm 4. Have mental capacity to understand study guidelines and questionnaires 5. Are capable to changing base plate and pouches without help. The help of a caregiver is accepted. 6. Experience leakage under the base plate at least one a week 7. Are currently using a flat 2-piece base plate with mechanical coupling 8. Have been evaluated by investigator (i.e. a health care professional) to have a stoma and peristomal skin condition that is acceptable for entering the study \-

Exclusion criteria

1. Pregnant or breast-feeding 2. Currently suffering from peristomal skin problems where the skin is damaged or bleeding (red and broken / broken and bleeding) as clinically evaluated by the investigator. 3. Currently receiving or have within the past 2 months received radio- and/or chemotherapy 4. Currently using steroid product on peristomal skin (injections and oral treatment are accepted) 5. Currently using a convex system 6. Participating in other clinical studies or have previously participated in this study

Design outcomes

Primary

MeasureTime frameDescription
Leakage Under the Base PlateAt every change of base plateArea of leakage under the base plate is recorded on a circular scale going from 0 fields to 24 fields where 0 is no leakage and 24 is complete leakage under the base plate.

Countries

Denmark

Participant flow

Recruitment details

Subjects were recruited from a user database in Denmark.

Pre-assignment details

41 subjects were enrolled, however 6 subjects did not comply with the inclusion and exclusion criteria. Four of these were terminated before testing any products. Whereas two subjects were included in the safety population as the inclusion criteria violation was first discovered after they tested a product.

Participants by arm

ArmCount
All Study Parcipitants
All parcipitants recieved all three intervention and they are therefore combined into one group.
35
Total35

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
First Period (14 +/- 3 Days)Protocol Violation200
Second Period (14 +/- 3 Days)Adverse Event210
Second Period (14 +/- 3 Days)Lack of Efficacy011
Third Period (14 +/- 3 Days)Adverse Event100
Third Period (14 +/- 3 Days)Lack of Efficacy100
Third Period (14 +/- 3 Days)not satisfied with product001

Baseline characteristics

CharacteristicAll Study Parcipitants
Age Continuous56 years
STANDARD_DEVIATION 13.6
Sex: Female, Male
Female
19 Participants
Sex: Female, Male
Male
16 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
6 / 351 / 336 / 34
serious
Total, serious adverse events
2 / 350 / 330 / 34

Outcome results

Primary

Leakage Under the Base Plate

Area of leakage under the base plate is recorded on a circular scale going from 0 fields to 24 fields where 0 is no leakage and 24 is complete leakage under the base plate.

Time frame: At every change of base plate

Population: ITT

ArmMeasureValue (MEAN)Dispersion
AtlasLeakage Under the Base Plate8.2 units on a scaleStandard Deviation 5
SenSuraLeakage Under the Base Plate5.5 units on a scaleStandard Deviation 4.8
Conform2Leakage Under the Base Plate8.0 units on a scaleStandard Deviation 4.9

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026